All In Biotech

Drug Trial Radar · NCT06437639

MEXIDOL® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG)

Prospective, Open, Comparative, Randomized Study of the Efficacy and Safety Evaluation of the Mexidol® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG)

Last checked: Nov 20, 2026Latest source record: Dec 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

80

Actual

Start

Sep 15, 2023

Primary completion

Nov 29, 2023

Study completion Feb 2, 2024

Sponsor

Lead sponsor
PharmasoftIndustry
Sponsor type
Industry
First posted
May 31, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hypothesis: The use of neurocytoprotectors helps restore the functional activity of mitochondria, improve the nervous activity of the retina and optic nerve, and stabilize the glaucomatous process.

Conditions

  • Primary Open-Angle Glaucoma (POAG)

Interventions

  • MexidolDrug

    Neurocytoprotector

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Degree of expression of mitochondrial dysfunctionTime frame: 90 days
  2. Dynamics of the structural and functional characteristics of mitochondriaTime frame: 90 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tyumen Scientific Center of the Russian Academy of Sciences

    Tyumen, Russian Federation, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.